Hedström, Anna Karin
Olsson, Tomas
Alfredsson, Lars
Funding for this research was provided by:
the Swedish Research Council for Health, Working Life and Welfare (2015-00195 and 2019-00697, 2015-00195 and 2019-00697, 2015-00195 and 2019-00697)
the Swedish Brain Foundation (FO-2020-0077, FO-2020-0077, FO-2020-0077)
MS forskningsfonden
NEURO Sweden
Vetenskapsrådet (2016-02349, 2016-02349)
Karolinska Institute
Article History
Received: 8 May 2021
Accepted: 21 September 2021
First Online: 27 October 2021
Competing interests
: Hedström has nothing to disclose. Olsson served on scientific advisory boards and received speaker honoraria Novartis, Merck, Biogen, Merck and Genzyme; received from Novartis and Biogen; and receives unrestricted MS research support from Novartis, Genzyme, Biogen, Merck, the Swedish Research Council and the Swedish Brain Foundation. Alfredsson received research support from the Swedish Medical Research Council, the Swedish Council for Health, Working Life and Welfare and the Swedish Brain Foundation; has received speaker honoraria from Biogen Idec and TEVA.